Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Treatment outcome of nasal natural killer/T-cell lymphoma

  • Lee, Hyun-Jin (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Sang-Wook (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Suh, Cheol-Won (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Huh, Joo-Ryung (Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Yoon, Sang-Min (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Young-Seok (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Su-San (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Jong-Hoon (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Choi, Eun-Kyung (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Ahn, Seung-Do (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine)
  • Received : 2011.07.04
  • Accepted : 2011.09.02
  • Published : 2011.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To evaluate the radiotherapy treatment outcome of patients in stage IE and IIE nasal natural killer/T-cell lymphoma. Materials and Methods: From August 1999 to August 2009, 46 patients with stage IE and IIE nasal natural killer/T-cell lymphoma were treated by definitive radiotherapy and chemotherapy. 33 patients were treated with chemotherapy followed by radiotherapy (CT + RT) and they received 50.4 Gy in 28 fractions. 13 patients were treated with concurrent chemoradiotherapy (CCRT) and they received 40 Gy in 20 fractions. Results: The median follow-up period was 4.6-137.6 months (median, 50.2 months) for all patients. The 4-year overall survival was 68.6% and 4-year disease free survival (DFS) was 61.9%. The 4-year locoregional recurrence free survival was 65.0%, and 4-year distant metastasis free survival (DMFS) was 66.2%. For patients treated with CT + RT, 15 patients (45.5%) achieved complete response after chemotherapy, and 13 patients (39.4%) achieved partial response. 13 patients (81.8%) achieved complete response after radiotherapy, and 6 patients (18.2%) achieved partial response. For patients treated with CCRT, 11 patients (84.6%) achieved complete response, and one patient (7.7%) achieved partial response. In univariate analysis, presence of cervical lymph node metastasis was only significant prognostic factor for DFS and DMFS. Conclusion: This study did not show satisfactory overall survival rate and disease free survival rate of definitive radiotherapy and chemotherapy for stage IE and IIE nasal natural killer/T-cell lymphoma. For patients with cervical lymph node metastasis, further investigation of new chemotherapy regimens is necessary to reduce the distant metastasis.

Keywords

References

  1. Jaffe ES, Chan JK, Su IJ, et al. Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas: definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 1996;20:103-11. https://doi.org/10.1097/00000478-199601000-00012
  2. Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/ T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 2009;113:3931-7. https://doi.org/10.1182/blood-2008-10-185256
  3. Kim GE, Cho JH, Yang WI, et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol 2000;18:54-63.
  4. Li CC, Tien HF, Tang JL, et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer 2004;100:366-75. https://doi.org/10.1002/cncr.11908
  5. Kim BS, Kim TY, Kim CW, et al. Therapeutic outcome of extranodal NK/T-cell lymphoma initially treated with chemotherapy: result of chemotherapy in NK/T-cell lymphoma. Acta Oncol 2003;42:779-83. https://doi.org/10.1080/02841860310010682
  6. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classifi cation of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-49.
  7. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998;339:21-6. https://doi.org/10.1056/NEJM199807023390104
  8. You JY, Chi KH, Yang MH, et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol 2004;15:618-25. https://doi.org/10.1093/annonc/mdh143
  9. Li YX, Coucke PA, Li JY, et al. Primary non-Hodgkin's lymphoma of the nasal cavity: prognostic significance of paranasal extension and the role of radiotherapy and chemotherapy. Cancer 1998;83:449-56. https://doi.org/10.1002/(SICI)1097-0142(19980801)83:3<449::AID-CNCR13>3.0.CO;2-W
  10. Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 2006;24:181-9. https://doi.org/10.1200/JCO.2005.03.2573
  11. Kim WS, Song SY, Ahn YC, et al. CHOP followed by involved fi eld radiation: is it optimal for localized nasal natural killer/ T-cell lymphoma? Ann Oncol 2001;12:349-52. https://doi.org/10.1023/A:1011144911781
  12. Kim SJ, Kim BS, Choi CW, et al. Treatment outcome of frontline systemic chemotherapy for localized extranodal NK/T cell lymphoma in nasal and upper aerodigestive tract. Leuk Lymphoma 2006;47:1265-73. https://doi.org/10.1080/10428190600565651
  13. Kim SJ, Kim K, Kim BS, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol 2009;27:6027-32. https://doi.org/10.1200/JCO.2009.23.8592
  14. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14. https://doi.org/10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
  15. Horning SJ, Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non- Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 2004;22:3032-8. https://doi.org/10.1200/JCO.2004.06.088
  16. Wang B, Lu JJ, Ma X, et al. Combined chemotherapy and external beam radiation for stage IE and IIE natural killer T-cell lymphoma of nasal cavity. Leuk Lymphoma 2007;48:396-402. https://doi.org/10.1080/10428190601059795
  17. Huang MJ, Jiang Y, Liu WP, et al. Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma, nasal-type in the upper aerodigestive tract. Int J Radiat Oncol Biol Phys 2008;70:166-74. https://doi.org/10.1016/j.ijrobp.2007.05.073
  18. Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 2002;54:182-90.
  19. Yamaguchi M, Tobinai K, Oguchi M, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 2009;27:5594-600. https://doi.org/10.1200/JCO.2009.23.8295
  20. Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006;24:612-8. https://doi.org/10.1200/JCO.2005.04.1384
  21. Kim TM, Park YH, Lee SY, et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood 2005;106:3785-90. https://doi.org/10.1182/blood-2005-05-2056
  22. Kim SJ, Kim BS, Choi CW, et al. Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type. Ann Oncol 2007;18:1382-7. https://doi.org/10.1093/annonc/mdm183

Cited by

  1. "Sandwich" Chemotherapy (CT) with Radiotherapy (RT) Improves Outcomes in Patients with Stage IE/IIE Extranodal Natural Killer (NK)/T-cell Lymphomas vol.14, pp.7, 2011, https://doi.org/10.7314/apjcp.2013.14.7.4061
  2. Sequential chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in patients with stage I/II extranodal natural killer/T-cell lymphoma, nasal type vol.48, pp.4, 2011, https://doi.org/10.5045/br.2013.48.4.274
  3. The significance of combining radiotherapy with chemotherapy for early stage extranodal natural killer/T-cell lymphoma, nasal type: a systematic review and meta-analysis vol.55, pp.5, 2014, https://doi.org/10.3109/10428194.2013.827789
  4. A systematic comparison of treatment modalities for nasal extranodal natural killer/T-cell lymphoma in early stages between concurrent chemoradiotherapy and sequential chemotherapy vol.10, pp.None, 2011, https://doi.org/10.2147/ott.s136386